Thomas Aparicio

13.2k total citations · 2 hit papers
254 papers, 6.5k citations indexed

About

Thomas Aparicio is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Thomas Aparicio has authored 254 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 150 papers in Oncology, 103 papers in Pulmonary and Respiratory Medicine and 74 papers in Surgery. Recurrent topics in Thomas Aparicio's work include Colorectal Cancer Treatments and Studies (97 papers), Gastric Cancer Management and Outcomes (84 papers) and Gastrointestinal Tumor Research and Treatment (42 papers). Thomas Aparicio is often cited by papers focused on Colorectal Cancer Treatments and Studies (97 papers), Gastric Cancer Management and Outcomes (84 papers) and Gastrointestinal Tumor Research and Treatment (42 papers). Thomas Aparicio collaborates with scholars based in France, Italy and United States. Thomas Aparicio's co-authors include P. Rougier, Olivier Bouché, Michel Ducreux, Aziz Zaanan, Julien Taı̈eb, Emmanuel Mitry, Thierry Lecomte, Laurent Bedenne, Iradj Sobhani and Pierre Laurent‐Puig and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Thomas Aparicio

236 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

2008 501 citations Olivier Bouché, Thomas Aparicio et al. Annals of Oncology profile →
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

2022 220 citations Thierry André, David Tougeron et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Aparicio France	40	3.6k	2.1k	1.8k	1.5k	1.1k	254	6.5k
Romain Coriat France	40	2.7k 0.8×	1.6k 0.8×	1.3k 0.7×	1.1k 0.8×	331 0.3×	287	5.2k
Marina Talamonti United States	46	4.8k 1.3×	2.0k 1.0×	2.6k 1.4×	1.0k 0.7×	364 0.3×	208	8.3k
Jón G. Jónasson Iceland	48	2.1k 0.6×	1.8k 0.9×	1.8k 1.0×	1.1k 0.8×	1.2k 1.0×	209	7.8k
Martin J. Heslin United States	41	3.1k 0.9×	2.1k 1.0×	2.0k 1.1×	609 0.4×	269 0.2×	142	6.2k
Mark S. Talamonti United States	35	3.8k 1.1×	1.6k 0.8×	2.3k 1.3×	1.7k 1.1×	608 0.5×	96	6.0k
Antonio Facciorusso Italy	52	2.6k 0.7×	2.0k 1.0×	2.6k 1.4×	2.3k 1.6×	629 0.6×	397	6.9k
Chun‐Nan Yeh Taiwan	41	1.7k 0.5×	2.2k 1.0×	2.7k 1.5×	676 0.5×	929 0.8×	280	5.5k
Gabriele Capurso Italy	47	4.3k 1.2×	1000 0.5×	3.0k 1.7×	3.0k 2.1×	643 0.6×	263	7.3k
Irene Floriani Italy	47	3.3k 0.9×	2.3k 1.1×	1.8k 1.0×	605 0.4×	400 0.3×	159	8.3k
Benjamin Tan United States	33	2.9k 0.8×	1.9k 0.9×	1.6k 0.9×	434 0.3×	886 0.8×	163	5.0k

Countries citing papers authored by Thomas Aparicio

Since Specialization

Citations

This map shows the geographic impact of Thomas Aparicio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Aparicio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Aparicio more than expected).

Fields of papers citing papers by Thomas Aparicio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Aparicio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Aparicio. The network helps show where Thomas Aparicio may publish in the future.

Co-authorship network of co-authors of Thomas Aparicio

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Aparicio. A scholar is included among the top collaborators of Thomas Aparicio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Aparicio. Thomas Aparicio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aparicio, Thomas, et al.. (2024). Management of esogastric cancer in older patients. Therapeutic Advances in Medical Oncology. 16. 12717677–12717677. 1 indexed citations

Walter, Thomas, Thierry Lecomte, Julien Hadoux, et al.. (2023). LBA54 Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: A randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network. Annals of Oncology. 34. S1292–S1293. 5 indexed citations

Rasola, Cosimo, Pierre Laurent‐Puig, Thierry André, et al.. (2023). Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer. European Journal of Cancer. 194. 113321–113321. 5 indexed citations

Baan, Frederieke H. van der, Romain Cohen, Thomas Aparicio, et al.. (2023). Prognostic value of Lynch syndrome, BRAF^V600E, and RAS mutational status in dMMR/MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts. Cancer Medicine. 12(15). 15841–15853. 7 indexed citations

Gouverneur, Amandine, Jérémy Jové, Francesco Salvo, et al.. (2023). Impact of Cardiovascular Comorbidities on the Effectiveness and Safety of Bevacizumab in Older Patients with Metastatic Colorectal Cancer. Targeted Oncology. 18(5). 717–726.

André, Thierry, David Tougeron, Guillaume Piessen, et al.. (2022). Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. Journal of Clinical Oncology. 41(2). 255–265. 220 indexed citations breakdown →

Ecker, Brett L., Lily V. Saadat, Thomas Aparicio, et al.. (2022). Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis. The Lancet Oncology. 23(10). 1332–1342. 30 indexed citations

François, Éric, Thomas Aparicio, Karine Le Malicot, et al.. (2022). SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer. Digestive and Liver Disease. 54(6). 747–754. 2 indexed citations

Aparicio, Thomas, Karine Le Malicot, Michel Ducreux, et al.. (2021). Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials. European Journal of Cancer. 153. 40–50. 4 indexed citations

10.

Salvatore, Lisa, Emilio Bria, Isabella Sperduti, et al.. (2021). Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies. Cancer Treatment Reviews. 97. 102202–102202. 16 indexed citations

11.

Abrahamowicz, Michał, Valérie Jooste, Thomas Aparicio, et al.. (2021). Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer. BMC Medical Research Methodology. 21(1). 14–14. 6 indexed citations

12.

Aparicio, Thomas, Florence Canouï‐Poitrine, Philippe Caillet, et al.. (2020). Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG). Digestive and Liver Disease. 52(5). 493–505. 14 indexed citations

13.

Gallois, Claire, Julien Taı̈eb, Delphine Le Corre, et al.. (2018). Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. Clinical Cancer Research. 24(19). 4745–4753. 24 indexed citations

14.

Pernot, Simon, Olivier Dubreuil, Thomas Aparicio, et al.. (2018). Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. British Journal of Cancer. 119(4). 424–428. 24 indexed citations

15.

Touchefeu, Yann, Rosine Guimbaud, Christophe Louvet, et al.. (2018). Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial. Gastric Cancer. 22(3). 577–586. 5 indexed citations

16.

Zaanan, Aziz, Isabelle Trouilloud, Mélanie Gauthier, et al.. (2014). FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. BMC Cancer. 14(1). 441–441. 27 indexed citations

17.

Aparicio, Thomas, Jean–Louis Jouve, Laurent Teillet, et al.. (2013). Geriatric Factors Predict Chemotherapy Feasibility: Ancillary Results of FFCD 2001-02 Phase III Study in First-Line Chemotherapy for Metastatic Colorectal Cancer in Elderly Patients. Journal of Clinical Oncology. 31(11). 1464–1470. 154 indexed citations

18.

Benamouzig, Robert, Bernard Uzzan, Gheorghe Airinei, et al.. (2013). Effects of Intragastric Balloon on Weight Loss, Physical Activity, Plasma Leptin and Ghrelin in Obese Patients, with Long-Term Follow-Up. Journal of Gastroenterology and Hepatology Research. 2(8). 744–749. 2 indexed citations

19.

Abolhassani, Mohammad, Thomas Aparicio, Nadine Martin‐Garcia, et al.. (2008). Leptin Receptor–Related Immune Response in Colorectal Tumors: The Role of Colonocytes and Interleukin-8. Cancer Research. 68(22). 9423–9432. 33 indexed citations

20.

Nguyen, Charles, Marc Faraggi, Anne‐Laure Giraudet, et al.. (2004). Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy.. PubMed. 45(10). 1660–8. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact